KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Retained Earnings (2016 - 2026)

NovoCure's Retained Earnings history spans 13 years, with the latest figure at -$1.4 billion for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 14.56% to -$1.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.4 billion, a 14.56% decrease, with the full-year FY2025 number at -$3.4 million, up 99.7% from a year prior.
  • Retained Earnings hit -$1.4 billion in Q1 2026 for NovoCure, down from -$3.4 million in the prior quarter.
  • Over the last five years, Retained Earnings for NVCR hit a ceiling of -$2.0 million in Q2 2023 and a floor of -$1.4 billion in Q1 2026.
  • Historically, Retained Earnings has averaged -$724.0 million across 5 years, with a median of -$831.5 million in 2023.
  • Biggest five-year swings in Retained Earnings: plummeted 35350.36% in 2022 and later soared 99.7% in 2025.
  • Tracing NVCR's Retained Earnings over 5 years: stood at -$778.5 million in 2022, then surged by 99.3% to -$5.5 million in 2023, then plummeted by 21003.13% to -$1.2 billion in 2024, then soared by 99.7% to -$3.4 million in 2025, then plummeted by 39466.84% to -$1.4 billion in 2026.
  • Business Quant data shows Retained Earnings for NVCR at -$1.4 billion in Q1 2026, -$3.4 million in Q4 2025, and -$1.3 billion in Q3 2025.